The data, shared by Dr. Courtney Crane, center on the drug's performance in both adult and pediatric populations. Initial results from a Phase 1a/b study indicate that MTX-101 is well-tolerated and may positively influence C-peptide levels. Further research, conducted alongside the University of Colorado, suggests that the mechanistic benefits observed in adults effectively translate to younger patients.

By targeting inhibitory KIR and CD8 on regulatory T cells, MTX-101 aims to selectively eliminate pathogenic T cells. This mechanism distinguishes the therapy from traditional treatments that suppress the entire immune system. Mozart Therapeutics is now preparing for a Phase 2a proof-of-concept study, with patient enrollment scheduled to begin in the first half of 2027.